We are live on ! Find out more
DBVT

DBV Technologies

78 hedge funds and large institutions have $346M invested in DBV Technologies in 2026 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 24 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 10

10% more funds holding

Funds holding: 7178 (+7)

1.68% less ownership

Funds ownership: 38.04%36.36% (-1.7%)

20% less capital invested

Capital invested by funds: $434M → $346M (-$87.9M)

29% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 24

67% less funds holding in top 10

Funds holding in top 10: 31 (-2)

Holders
78
Holders Change
+7
Holders Change %
+9.86%
% of All Funds
0.94%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.01%
New
17
Increased
17
Reduced
24
Closed
10
Calls
Puts
Net Calls
Net Calls Change

DBVT Hedge Fund Activity: Q2 2026 in Review

78 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in DBV Technologies (DBVT) for Q2 2026, worth a combined $346M — down 20% from $434M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new DBVT positions and 10 closed out — a net gain of 7 holders — while 17 added to existing stakes and 24 trimmed.

The largest buyer was UBS Group, adding an estimated $23.3M. The largest seller was MPM BioImpact, cutting an estimated $29.2M.

  • 78 institutional investors held DBV Technologies (DBVT) as of Q2 2026, up from 71 in Q1 2026.
  • Funds reported $346M of DBV Technologies stock for Q2 2026, down 20% quarter-over-quarter.
  • 17 funds opened new DBV Technologies positions in Q2 2026 and 10 closed out, a net change of +7 holders.
  • The largest DBV Technologies buyer in Q2 2026 was UBS Group, an estimated $23.3M added.
  • The largest DBV Technologies seller in Q2 2026 was MPM BioImpact, an estimated $29.2M sold.

Based on aggregated 13F filings for Q2 2026.